ClinicalTrials.gov: ReMIND trial | Source Library

Trial registryClinical trial registry

Source type: Trial registry
Access type: Official
Publisher: ClinicalTrials.gov
Date: 2026
Added: 2026-06-30

Trust profile

VV Source Trust Matrix v1.0

VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.

Clinical trial registry

Publisher type: Trial registry
Bias profile: Moderate

This source is strongest for trial discovery and safety and weaker for mechanism and consumer context.

VV Source Fit Score 1.0

Fit by use case

Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.

Frameworks ->

Regulatory status: 64/100; Context Source
Clinical outcomes: 67/100; Context Source
Mechanism: 64/100; Context Source
Safety: 71/100; Context Source
Consumer context: 64/100; Context Source
Trial discovery: 92/100; Primary Anchor

Best used for

Trial status
Protocol and endpoint discovery

Weak for

Unpublished results
Clinical conclusions

Used in Viral Vitalism

Backgroundbrief1 reference

First-in-Human T-Cell Therapy Targets Three Proteins in Pediatric Brain Tumors

Roles: Background

Show section-level references

Researchers reported that systemically delivered autologous T cells targeting WT1, PRAME, and survivin met Phase 1 safety and feasibility endpoints in pediatric and young adult CNS tumor patients, with preliminary disease-control signals in some patients.

Related studies

No structured study record is currently attached to this source.